Intellia, ReCode partner to develop gene editing therapies for cystic fibrosis
The partnership will combine Intellia's patented CRISPR-based gene editing platform with ReCode's Selective Organ Targeting (SORT) lipid nanoparticle…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 Feb 24
The partnership will combine Intellia's patented CRISPR-based gene editing platform with ReCode's Selective Organ Targeting (SORT) lipid nanoparticle…
15 Feb 24
NM49 is a multi-specific antibody designed to activate tumour associated macrophage phagocytosis to treat cancers and identified through…
14 Feb 24
Financing led by Ally Bridge Group, bolstered by contributions from world-class healthcare dedicated and mutual fund institutional investors,…
13 Feb 24
Under the terms of the new agreement, Pfizer will keep scaling SDQ in order to help expedite and…
12 Feb 24
Both firms will assess BI-1206 in combination with rituximab and Calquence to treat patients with follicular lymphoma who…
06 Feb 24
Under the partnership, both firms will start a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in…
06 Feb 24
The collaboration, includes MGI's first corporate order of the revolutionary DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in the Middle…
31 Jan 24
This platformization of new technologies will enable our clients to accelerate the discovery of preclinical ADC candidates (PCCs)…
31 Jan 24
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment…
25 Jan 24
Derived from the company’s WuXia cell line platform, WuXia ADCC PLUS is a superior-performing and high-yielding mammalian cell…